Alzheimer's Disease and Specialized Pro-Resolving Lipid Mediators: Do MaR1, RvD1, and NPD1 Show Promise for Prevention and Treatment?

Overview

Journal Int J Mol Sci

Publisher MDPI

Specialties Biochemistry
Chemistry
Molecular Biology

Date 2020 Aug 19

PMID 32806612

Citations 12

Authors

Keishi Miyazawa

Hisanori Fukunaga

Yasuko Tatewaki

Yumi Takano

Shuzo Yamamoto

Tatsushi Mutoh

Yasuyuki Taki

Affiliations

Soon will be listed here.

Abstract

Alzheimer's disease (AD) is a common neurodegenerative disease and a major contributor to progressive cognitive impairment in an aging society. As the pathophysiology of AD involves chronic neuroinflammation, the resolution of inflammation and the group of lipid mediators that actively regulate it-i.e., specialized pro-resolving lipid mediators (SPMs)-attracted attention in recent years as therapeutic targets. This review focuses on the following three specific SPMs and summarizes their relationships to AD, as they were shown to effectively address and reduce the risk of AD-related neuroinflammation: maresin 1 (MaR1), resolvin D1 (RvD1), and neuroprotectin D1 (NPD1). These three SPMs are metabolites of docosahexaenoic acid (DHA), which is contained in fish oils and is thus easily available to the public. They are expected to become incorporated into promising avenues for preventing and treating AD in the future.

Citing Articles

The Application of Resolvin D1-Loaded Gelatin Methacrylate in a Rat Periodontitis Model.

Xing Z, Liu J, Cai J, Jiang X, Liang J, Fujio M Pharmaceutics. 2025; 17(1).

PMID: 39861667 PMC: 11768520. DOI: 10.3390/pharmaceutics17010016.

Lipid-mediated resolution of inflammation and survival in amyotrophic lateral sclerosis.

Yildiz O, Hunt G, Schroth J, Dhillon G, Spargo T, Al-Chalabi A Brain Commun. 2025; 7(1):fcae402.

PMID: 39816195 PMC: 11733686. DOI: 10.1093/braincomms/fcae402.

The Dual Role of Amyloid Beta-Peptide in Oxidative Stress and Inflammation: Unveiling Their Connections in Alzheimer's Disease Etiopathology.

Fanlo-Ucar H, Picon-Pages P, Herrera-Fernandez V, Ill-Raga G, Munoz F Antioxidants (Basel). 2024; 13(10).

PMID: 39456461 PMC: 11505517. DOI: 10.3390/antiox13101208.

Understanding the effects of omega-3 fatty acid supplementation on the physical properties of brain lipid membranes.

Longarzo M, Vazquez R, Bellini M, Zamora R, Redondo-Morata L, Giannotti M iScience. 2024; 27(7):110362.

PMID: 39071883 PMC: 11277689. DOI: 10.1016/j.isci.2024.110362.

Integration of plasma and CSF metabolomics with CSF proteomic reveals novel associations between lipid mediators and central nervous system vascular and energy metabolism.

Borkowski K, Seyfried N, Arnold M, Lah J, Levey A, Hales C Sci Rep. 2023; 13(1):13752.

PMID: 37612324 PMC: 10447532. DOI: 10.1038/s41598-023-39737-8.

References

Heneka M, Carson M, El Khoury J, Landreth G, Brosseron F, Feinstein D . Neuroinflammation in Alzheimer's disease. Lancet Neurol. 2015; 14(4):388-405. PMC: 5909703. DOI: 10.1016/S1474-4422(15)70016-5. View

Serhan C . Pro-resolving lipid mediators are leads for resolution physiology. Nature. 2014; 510(7503):92-101. PMC: 4263681. DOI: 10.1038/nature13479. View

Serhan C, Chiang N, Dalli J . The resolution code of acute inflammation: Novel pro-resolving lipid mediators in resolution. Semin Immunol. 2015; 27(3):200-15. PMC: 4515371. DOI: 10.1016/j.smim.2015.03.004. View

Mizwicki M, Liu G, Fiala M, Magpantay L, Sayre J, Siani A . 1α,25-dihydroxyvitamin D3 and resolvin D1 retune the balance between amyloid-β phagocytosis and inflammation in Alzheimer's disease patients. J Alzheimers Dis. 2012; 34(1):155-70. PMC: 4040018. DOI: 10.3233/JAD-121735. View

Martinsen A, Tejera N, Vauzour D, Harden G, Dick J, Shinde S . Altered SPMs and age-associated decrease in brain DHA in female mice. FASEB J. 2019; 33(9):10315-10326. DOI: 10.1096/fj.201900423R. View

Wang J, Tan L, Wang H, Tan C, Meng X, Wang C . Anti-inflammatory drugs and risk of Alzheimer's disease: an updated systematic review and meta-analysis. J Alzheimers Dis. 2014; 44(2):385-96. DOI: 10.3233/JAD-141506. View

Waechter V, Schmid M, Herova M, Weber A, Gunther V, Marti-Jaun J . Characterization of the promoter and the transcriptional regulation of the lipoxin A4 receptor (FPR2/ALX) gene in human monocytes and macrophages. J Immunol. 2012; 188(4):1856-67. DOI: 10.4049/jimmunol.1101788. View

Heneka M, Golenbock D, Latz E . Innate immunity in Alzheimer's disease. Nat Immunol. 2015; 16(3):229-36. DOI: 10.1038/ni.3102. View

Emre C, Hjorth E, Bharani K, Carroll S, Granholm A, Schultzberg M . Receptors for pro-resolving mediators are increased in Alzheimer's disease brain. Brain Pathol. 2020; 30(3):614-640. PMC: 8018009. DOI: 10.1111/bpa.12812. View

10.

Sobrado M, Pereira M, Ballesteros I, Hurtado O, Fernandez-Lopez D, Pradillo J . Synthesis of lipoxin A4 by 5-lipoxygenase mediates PPARgamma-dependent, neuroprotective effects of rosiglitazone in experimental stroke. J Neurosci. 2009; 29(12):3875-84. PMC: 6665034. DOI: 10.1523/JNEUROSCI.5529-08.2009. View

11.

Bondue B, Wittamer V, Parmentier M . Chemerin and its receptors in leukocyte trafficking, inflammation and metabolism. Cytokine Growth Factor Rev. 2011; 22(5-6):331-8. DOI: 10.1016/j.cytogfr.2011.11.004. View

12.

Dullemeijer C, Durga J, Brouwer I, van de Rest O, Kok F, Brummer R . n 3 fatty acid proportions in plasma and cognitive performance in older adults. Am J Clin Nutr. 2007; 86(5):1479-85. DOI: 10.1093/ajcn/86.5.1479. View

13.

Akiyama H, Barger S, Barnum S, Bradt B, Bauer J, Cole G . Inflammation and Alzheimer's disease. Neurobiol Aging. 2000; 21(3):383-421. PMC: 3887148. DOI: 10.1016/s0197-4580(00)00124-x. View

14.

Serhan C . Discovery of specialized pro-resolving mediators marks the dawn of resolution physiology and pharmacology. Mol Aspects Med. 2017; 58:1-11. PMC: 5582020. DOI: 10.1016/j.mam.2017.03.001. View

15.

Maddox J, Hachicha M, Takano T, Petasis N, Fokin V, Serhan C . Lipoxin A4 stable analogs are potent mimetics that stimulate human monocytes and THP-1 cells via a G-protein-linked lipoxin A4 receptor. J Biol Chem. 1997; 272(11):6972-8. DOI: 10.1074/jbc.272.11.6972. View

16.

Famenini S, Rigali E, Olivera-Perez H, Dang J, Chang M, Halder R . Increased intermediate M1-M2 macrophage polarization and improved cognition in mild cognitive impairment patients on ω-3 supplementation. FASEB J. 2016; 31(1):148-160. PMC: 5161513. DOI: 10.1096/fj.201600677RR. View

17.

Shen Y, Lue L, Yang L, Roher A, Kuo Y, Strohmeyer R . Complement activation by neurofibrillary tangles in Alzheimer's disease. Neurosci Lett. 2001; 305(3):165-8. DOI: 10.1016/s0304-3940(01)01842-0. View

18.

Mohri I, Kadoyama K, Kanekiyo T, Sato Y, Kagitani-Shimono K, Saito Y . Hematopoietic prostaglandin D synthase and DP1 receptor are selectively upregulated in microglia and astrocytes within senile plaques from human patients and in a mouse model of Alzheimer disease. J Neuropathol Exp Neurol. 2007; 66(6):469-80. DOI: 10.1097/01.jnen.0000240472.43038.27. View

19.

Serhan C, Petasis N . Resolvins and protectins in inflammation resolution. Chem Rev. 2011; 111(10):5922-43. PMC: 3192290. DOI: 10.1021/cr100396c. View

20.

Moncada S, Gryglewski R, Bunting S, Vane J . An enzyme isolated from arteries transforms prostaglandin endoperoxides to an unstable substance that inhibits platelet aggregation. Nature. 1976; 263(5579):663-5. DOI: 10.1038/263663a0. View